Pfizer Inc
NYSE:PFE
Relative Value
The Relative Value of one PFE stock under the Base Case scenario is 34.495 USD. Compared to the current market price of 25.355 USD, Pfizer Inc is Undervalued by 26%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
PFE Competitors Multiples
Pfizer Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Pfizer Inc
NYSE:PFE
|
143.2B USD | 2.4 | 67.3 | 10.3 | 15.2 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
696B USD | 20.4 | 132.8 | 60 | 68.9 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 17 | 47.1 | 34.5 | 37.6 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
JP |
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 255.8 | 9 733.7 | 1 771.8 | 4 320.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
352.9B USD | 4.3 | 8.7 | 11.6 | 15.3 | ||
US |
Merck & Co Inc
NYSE:MRK
|
332.6B USD | 5.5 | 911.2 | 45.2 | 88.3 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
185.5B GBP | 5 | 38.8 | 140.4 | 225.3 | ||
CH |
Novartis AG
SIX:NOVN
|
183.1B CHF | 4.3 | 13.5 | 9.9 | 16.3 | ||
CH |
Roche Holding AG
SIX:ROG
|
176.4B CHF | 3 | 15.3 | 8.5 | 10 |